Comparison · NCT03123588-ecd21a81
Group A : Ruxolitinib and Anagrelide Placebo vs Group B : Anagrelide and Ruxolitinib PLacebo: Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Group A : Ruxolitinib and Anagrelide Placebo vs Group B : Anagrelide and Ruxolitinib PLacebo: Number of Participants With Treatment Emergent Adverse Events (TEAEs). Trial comparisons, record NCT03123588-ecd21a81. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03123588-ecd21a81
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 1 | 0.566 | 1 | wilson | |
| Risk in group 2 | 0.667 | 0.3 | 0.903 | wilson | |
| Risk difference, group 1 minus group 2 | 0.333 | -0.161 | 0.7 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.5 | 0.852 | 2.64 | log | |
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat, for one more participant with the outcome on Group A : Ruxolitinib and Anagrelide Placebo than on Group B : Anagrelide and Ruxolitinib PLacebo | 3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Group A : Ruxolitinib and Anagrelide Placebo | Ruxolitinib or placebo will be administered orally twice a day at a starting dose of 10 mg. | 5 | 5 | OG000 |
| Group 2 | Group B : Anagrelide and Ruxolitinib PLacebo | Anagrelide or placebo will be administered orally twice a day at a starting dose of 1 mg. Use of anagrelide will be consistent with approved prescribing information. | 4 | 6 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Treatment Emergent Adverse Events (TEAEs)
- Description
- Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment.
- Time frame
- Baseline through the end of randomized period -up to 14 months per participant
- Population
The safety population includes all randomized subjects who received at least 1 dose of study drug. AE has been summarized only in randomized period. End of randomized period is defined as the earliest of discontinuation or the individual unblinding date.
Source ClinicalTrials.gov
Trial
- Title
- Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
- NCT number
- NCT03123588
- Phases
- PHASE2
- Conditions
- MPN (Myeloproliferative Neoplasms)
- Interventions
- Ruxolitinib, Anagrelide, Placebo, Placebo
- Lead sponsor
- Incyte Corporation
- Results first posted
- 2021-11-19
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03123588?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03123588-ecd21a81